Amino Acid Supplementation in Continuous Renal Replacement Therapy

Last updated: February 14, 2025
Sponsor: Karolinska University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Kidney Disease

Renal Failure

Kidney Failure

Treatment

Amino acid supplementation (Glavamin, Fresenius Kabi)

Clinical Study ID

NCT06835816
2023-07570-01
  • Ages > 18
  • All Genders

Study Summary

ICU patients treated with continuous renal replacement therapy is recruited prior to start of treatment.

Blood samples are drawn and then dialysis start without amino acid supplementation. After a few hours samples are drawn from blood and dialysate. Then patients are given amino acid supplementation (33.5g/24hrs) for 20-24 hours. New samples are drawn and amino acid supplementation is increased to 67g/24hrs and new samples are drawn after additional 24 hours. Then CRRT will continue with the full amino acid supplementation (standars of care).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Dialysis where amino acid supplementation is planned by treating physician

Exclusion

Exclusion Criteria:

  • Liver failure

  • Muscle disease

  • Neurodegenerative disease

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Amino acid supplementation (Glavamin, Fresenius Kabi)
Phase:
Study Start date:
February 03, 2025
Estimated Completion Date:
December 31, 2028

Connect with a study center

  • Karolinska University Hospital

    Stockholm, 14186
    Sweden

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.